When J&J Buys Your Trial: What the Ollin Acquisition Means for Site Activation and Budget Reality
J&J's $2.2B Ollin buyout and $750M Blackstone funding deal create an immediate Phase 3 integration challenge, here's what sponsor...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
J&J's $2.2B Ollin buyout and $750M Blackstone funding deal create an immediate Phase 3 integration challenge, here's what sponsor...
At a CDER webinar on drug interaction labeling, FDA officials drew the lines sponsors most often blur: contraindicate versus...
Medrio launches connected CTMS to automatically integrate EDC and eTMF data, reducing manual reconciliation and integration costs for clinical...
Prelude Therapeutics advances PRT13722 into Phase 1 testing with $142.7M in cash, managing three parallel clinical programs simultaneously.
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...
CRB-913 achieved 5% mean weight loss in Phase 1b obesity trial, with all doses showing statistical significance against placebo...
Lexeo's LX2020 earns FDA RMAT designation for PKP2 cardiomyopathy, enabling expedited development based on interim Phase I/II data.
Five-year lecanemab data shows 62% of early Alzheimer's patients with low tau levels demonstrated cognitive improvement, with widening benefits...
FDA Rejects ivonescimab BLA due to missing overall survival data. Summit Therapeutics' lung cancer therapy blocked despite progression-free survival...
A decade in patient recruitment did not prepare her for what it felt like to be on the other...